$208.13
▼ -0.9% Today
as of Sep 4, 16:54 ET
Last 30 days
Recent Press Releases & News
lean bull
▲ 5
● 20
▼ 0
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Overview
52-week range
$40
$224
91% of range
Avg surprise (last 3)
-21.8%
Avg reaction (last 2)
+1.6%
100% positive
Latest IV / EM
44%
EM ±6.9% · $210 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-3.06 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $-2.29 | $-1.83 | -25.1% | -102.7% | +2.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.61 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-1.31 | $-0.94 | -39.4% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-1.13 | $-1.12 | -0.9% | — | +0.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.94 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.81 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.70 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.99 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.92 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.72 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-505M | $-445M | — | $-315M | $-265M | $-241M | — | $-176M |
| Net income | $-644M | $-454M | — | $-305M | $-248M | $-213M | — | $-156M |
| EPS (diluted) | $-3.06 | $-2.29 | — | $-1.61 | $-1.31 | $-1.13 | — | $-0.94 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $815M | $441M | $384M | $217M | $402M | $334M | $543M | $201M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $4.03B | $1.97B | $2.08B | $1.98B | $2.18B | $2.13B | $2.33B | $1.58B |
| Total assets | $4.32B | $2.25B | $2.35B | $2.25B | $2.43B | $2.37B | $2.56B | $1.76B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1.72B | $754M | $723M | $655M | $564M | $287M | $293M | $197M |
| Total equity | $2.61B | $1.50B | $1.63B | $1.60B | $1.87B | $2.08B | $2.27B | $1.57B |